fda and compounded glp 1 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Today, the FDA is announcing

Results Global metabolomics We started by selecting three assays, including HILICpos, HILICneg, and C18pos, based on data quality as measured with global metabolomics (G-Met) in a previous report published by us 28

COAs are batch-specific and available on the Lab Tests page

Dugosz et al., 2025)

Pese a las advertencias que hizo el Instituto de Salud Pblica (ISP) y el Servicio Nacional del Consumidor (Sernac ), todava es posible encontrar en el mercado (principalmente en internet) los cuestionados GLP -1 Patches

This risk is especially pronounced in endometrial and embryo datasets, where timing and laboratory context are tightly coupled to molecular readouts [296, 299, 462, 466]

4.9 Effects on general anaesthesia One of the major concerning side effects of GLP-1RA use in anesthesia are the complications of the GI tract presenting as delayed gastric emptying and elevated gastric residual content along with other symptoms (nausea, vomiting, abdominal distension and dyspepsia) (106)